Besides their immunomodulatory activity, the benefit conferred by HDAC inhibitors may be contingent upon their ability to enhance the expression of antigens of tumor cells targeted by therapeutic monoclonal antibodies, including the anti-CD38 antibody daratumumab. Here, CD38 is linked to neoplasm.